Murine skin and soft tissue infection model is utilized for assessing the virulence function of methicillin resistant Staphylococcus aureus (MRSA) and the host immunological responses. Here, we presented a subcutaneous infection model for skin and soft tissue infection.
MRSA is a worldwide threat to public health, and MRSA skin and soft-tissue infections now account for more than half of all soft-tissue infections in the United States. Among soft-tissue infections, myositis, pyomyositis, and necrotizing fasciitis have been increasingly reported in association with MRSA arising from the community. To understand the interplay between MRSA and host immunity leading to more severe infection, the availability of animal models is critical, permitting the study of host and bacterial factors. Several infection models have been introduced to assess the pathogenesis of S. aureus during superficial skin infection. Here, we describe a subcutaneous infection model that examines the skin, subcutaneous, and muscle pathologies.
1. Preparing the MRSA for Infection (two Days Prior to Infection)
2. Preparing the Mice for Infection (one Day Prior to Infection)
3. Preparing the MRSA for Infection (on the Day of Infection)
4. Subcutaneous Infection of MRSA (on the Day of Infection and 3 Days Post-infection)
5. Representative Results:
Figure 1. The skin and muscle lesions. CD1 mice were inoculated subcutaneous on one flank with MRSA (LAC). Pictures were taken at time 0 and day 3 post-infection. (A) Time 0 post-infection (p.i.), (B)-(G) Day 3 p.i.; B, D. and F: skin lesions; C, E, and G: muscle lesions; B and C: 1x 109 CFU infected; D and E: 1x 107 CFU infected; F and G: mock.
Figure 2. Skin lesion size and viable bacteria count at the infection site on day 3 post-infection. Skin and muscle lesions on MRSA (LAC) infected CD1 mice. (A) Skin lesion size. (B) Muscle lesion size. (C) Total tissue CFU. H: 1 x 109 CFU inocula; L: 1 x 107 CFU inocula. *: p < 0.05, Mann-Whitney test.
The authors have nothing to disclose.
This work was supported by a Burroughs-Wellcome Career Award and by National Institutes of Health grant AI074832 to G. Y. Liu.
Material Name | Tip | Company | Catalogue Number | Comment |
---|---|---|---|---|
THB | VWR | 95025-314 | ||
DPBS | Invitrogen | 21-031-CV | ||
1 ml syringe | BD | 309602 | ||
27G1/2 needle | BD | 305109 | ||
Sheep Blood Agar (TSA) | VWR | 90004-328 |